Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (12): 1419-1425.doi: 10.12092/j.issn.1009-2501.2021.12.012

Previous Articles     Next Articles

General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs

LI Na, HAN Hongcan, WANG Jun   

  1. Center of Drug Evaluation, National Medical Products Administration, Beijing 100022, China
  • Received:2021-11-10 Revised:2021-11-24 Online:2021-12-26 Published:2022-01-07

Abstract: On account of the characteristics of anti-schizophrenic drugs, combined with the technical guidelines for bioequivalence studies of anti-schizophrenic generic drugs in different regulatory institutions at home and abroad, taking some drugs as examples, this paper discusses the key points to be considered in carrying out bioequivalence studies from the perspective of experimental design, so as to provide certain reference for the research and development and evaluation of related products.

Key words: schizophrenia, generic drugs, bioequivalence studies, clozapine, quetiapine fumarate

CLC Number: